NCT02819843 2025-01-29
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
Clinical Trials
8 trialsNCT04068181 2025-01-07
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
Amgen
Phase 2 Completed
NCT03458117 2022-03-18
20139157 T-VEC
University of Zurich
Phase 1 Completed
NCT02366195 2021-11-30
TVEC-325
Amgen
Phase 2 Completed
NCT03555032 2021-08-18
TITAN
Royal Marsden NHS Foundation Trust
Phase 1/2 Completed
NCT02014441 2019-11-20
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
Amgen
Phase 2 Completed
NCT00289016 2015-12-18
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
BioVex Limited
Phase 2 Completed
NCT02574260 2015-12-17
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
BioVex Limited
Phase 2 Completed